Literature DB >> 7903197

Antitumor effect of taxol-containing liposomes in a taxol-resistant murine tumor model.

A Sharma1, E Mayhew, R M Straubinger.   

Abstract

Taxol is a promising agent for use in ovarian cancer and other malignancies. One problem associated with taxol is its low aqueous solubility, requiring Cremophor EL (polyethoxylated castor oil) and ethanol as excipients (Diluent 12); these agents cause serious adverse effects. Liposomes containing taxol and phospholipid (in a 1:33 mole ratio, respectively) were prepared from phosphatidylglycerol and phosphatidylcholine in a 1:9 mole ratio. Antitumor effect was evaluated against Colon-26, a taxol-resistant murine tumor. Given as 1, 4, or 9 injections, free taxol given i.v. in Diluent 12 was ineffective at delaying tumor growth at doses < or = 30 mg/kg per injection (the maximum tolerated dose). In contrast, taxol-liposomes were well tolerated at doses greater than or equal to the maximum tolerated dose of free taxol and showed significant tumor growth inhibition at 10-45 mg/kg per injection.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7903197

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  24 in total

1.  A differential scanning calorimetry study of phosphocholines mixed with paclitaxel and its bromoacylated taxanes.

Authors:  S Ali; S Minchey; A Janoff; E Mayhew
Journal:  Biophys J       Date:  2000-01       Impact factor: 4.033

Review 2.  Liposomal drug formulations. Rationale for development and what we can expect for the future.

Authors:  T M Allen
Journal:  Drugs       Date:  1998-11       Impact factor: 9.546

3.  Comparison of two pharmacodynamic transduction models for the analysis of tumor therapeutic responses in model systems.

Authors:  Jun Yang; Donald E Mager; Robert M Straubinger
Journal:  AAPS J       Date:  2009-11-10       Impact factor: 4.009

4.  Molecular dynamics simulations of DPPC bilayers using "LIME", a new coarse-grained model.

Authors:  Emily M Curtis; Carol K Hall
Journal:  J Phys Chem B       Date:  2013-04-16       Impact factor: 2.991

5.  Pharmacokinetics and tissue distribution of PGG-paclitaxel, a novel macromolecular formulation of paclitaxel, in nu/nu mice bearing NCI-460 lung cancer xenografts.

Authors:  Xinghe Wang; Gang Zhao; Sang Van; Nan Jiang; Lei Yu; David Vera; Stephen B Howell
Journal:  Cancer Chemother Pharmacol       Date:  2009-07-11       Impact factor: 3.333

Review 6.  Liposomal formulations of cytotoxic drugs.

Authors:  R Janknegt
Journal:  Support Care Cancer       Date:  1996-07       Impact factor: 3.603

7.  Pharmacokinetics of paclitaxel-containing liposomes in rats.

Authors:  Gerald J Fetterly; Robert M Straubinger
Journal:  AAPS PharmSci       Date:  2003-11-21

8.  Differential pharmacodynamic effects of paclitaxel formulations in an intracranial rat brain tumor model.

Authors:  Rong Zhou; Richard V Mazurchuk; Judith H Tamburlin; John M Harrold; Donald E Mager; Robert M Straubinger
Journal:  J Pharmacol Exp Ther       Date:  2009-10-27       Impact factor: 4.030

9.  Novel taxol formulations: preparation and characterization of taxol-containing liposomes.

Authors:  A Sharma; R M Straubinger
Journal:  Pharm Res       Date:  1994-06       Impact factor: 4.200

10.  Preclinical efficacy studies of a novel nanoparticle-based formulation of paclitaxel that out-performs Abraxane.

Authors:  Zhongling Feng; Gang Zhao; Lei Yu; David Gough; Stephen B Howell
Journal:  Cancer Chemother Pharmacol       Date:  2009-08-15       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.